KMT2A and cancer: Shin MH et al. reported that targeting RUNX2/Menin/MLL1/MYC axis was a feasible strategy for killing p53 defective cancer cells, and two inhibitors Mi-2 and Mi-3 of the Menin/MLL1 complex induced apoptosis in p53 defective cancer cells [33].